<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="Hashemian et al http://orcid.org/0000-0002-0768-9168HashemianSeyed MohammadReza12FarhadiTayebeh2VelayatiAli Akbar2[1], National Research Institute of" exact="Tuberculosis" post="and Lung Disease (NRITLD), Shahid Beheshti University of Medical"/>
 <result pre="http://orcid.org/0000-0002-0768-9168HashemianSeyed MohammadReza12FarhadiTayebeh2VelayatiAli Akbar2[1], National Research Institute of Tuberculosis and Lung" exact="Disease" post="(NRITLD), Shahid Beheshti University of Medical SciencesTehranIran[2], National Research"/>
 <result pre="Shahid Beheshti University of Medical SciencesTehranIran[2], National Research Institute of" exact="Tuberculosis" post="and Lung Diseases (NRITLD), Shahid Beheshti University of Medical"/>
 <result pre="University of Medical SciencesTehranIran[2], National Research Institute of Tuberculosis and" exact="Lung Diseases" post="(NRITLD), Shahid Beheshti University of Medical SciencesTehranIran Correspondence: Tayebeh"/>
 <result pre="of Medical SciencesTehranIran[2], National Research Institute of Tuberculosis and Lung" exact="Diseases" post="(NRITLD), Shahid Beheshti University of Medical SciencesTehranIran Correspondence: Tayebeh"/>
 <result pre="(NRITLD), Shahid Beheshti University of Medical SciencesTehranIran Correspondence: Tayebeh Farhadi" exact="Chronic" post="Respiratory Diseases Research Center (CRDRC), National Research Institute of"/>
 <result pre="Shahid Beheshti University of Medical SciencesTehranIran Correspondence: Tayebeh Farhadi Chronic" exact="Respiratory" post="Diseases Research Center (CRDRC), National Research Institute of Tuberculosis"/>
 <result pre="Beheshti University of Medical SciencesTehranIran Correspondence: Tayebeh Farhadi Chronic Respiratory" exact="Diseases" post="Research Center (CRDRC), National Research Institute of Tuberculosis and"/>
 <result pre="Chronic Respiratory Diseases Research Center (CRDRC), National Research Institute of" exact="Tuberculosis" post="and Lung Diseases (NRITLD), Shahid Beheshti University of Medical"/>
 <result pre="Diseases Research Center (CRDRC), National Research Institute of Tuberculosis and" exact="Lung Diseases" post="(NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran"/>
 <result pre="Research Center (CRDRC), National Research Institute of Tuberculosis and Lung" exact="Diseases" post="(NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran"/>
 <result pre="Abstract Abstract The novel coronavirus 2019 (2019-nCoV), formally named severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2), is a novel human"/>
 <result pre="Abstract The novel coronavirus 2019 (2019-nCoV), formally named severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2), is a novel human infectious"/>
 <result pre="The novel coronavirus 2019 (2019-nCoV), formally named severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2), is a novel human infectious coronavirus."/>
 <result pre="acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is a novel human" exact="infectious" post="coronavirus. The disease caused by SARS-CoV-2 is named COVID-19."/>
 <result pre="coronavirus 2 (SARS-CoV-2), is a novel human infectious coronavirus. The" exact="disease" post="caused by SARS-CoV-2 is named COVID-19. Development and manufacturing"/>
 <result pre="a phosphoramidate prodrug of an adenosine C-nucleoside. By entrance into" exact="respiratory" post="epithelial cells in human, the prodrug is metabolized to"/>
 <result pre="phosphoramidate prodrug of an adenosine C-nucleoside. By entrance into respiratory" exact="epithelial" post="cells in human, the prodrug is metabolized to a"/>
 <result pre="triphosphate as the active form. The nucleoside analog inhibits the" exact="viral" post="RNA-dependent RNA polymerase (RdRp) by competing with the usual"/>
 <result pre="generating RNA strand and causes a delayed stop in the" exact="viral" post="replication process. Knowledge about the potential efficacy of remdesivir"/>
 <result pre="page-count: Introduction The novel coronavirus 2019 (2019-nCoV), formally named severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2), is a novel human"/>
 <result pre="Introduction The novel coronavirus 2019 (2019-nCoV), formally named severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2), is a novel human infectious"/>
 <result pre="The novel coronavirus 2019 (2019-nCoV), formally named severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2), is a novel human infectious coronavirus."/>
 <result pre="acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is a novel human" exact="infectious" post="coronavirus. COVID-19 is the disease caused by SARS-CoV-2. The"/>
 <result pre="(SARS-CoV-2), is a novel human infectious coronavirus. COVID-19 is the" exact="disease" post="caused by SARS-CoV-2. The disease was initially found in"/>
 <result pre="infectious coronavirus. COVID-19 is the disease caused by SARS-CoV-2. The" exact="disease" post="was initially found in Wuhan at the end of"/>
 <result pre="2019 and spread rapidly around the world. The number of" exact="infectious" post="patients has increased worldwide, resulting in a pandemic situation.1"/>
 <result pre="may be valuable to treat the clinical symptoms of the" exact="infection" post="such as cough, fever and difficulty breathing.2 SARS-CoV-2 shares"/>
 <result pre="breathing.2 SARS-CoV-2 shares an 80% RNA sequence homology with the" exact="acute" post="respiratory syndrome-associated coronavirus (SARS-CoV).2,3 Some enzymes of both viruses"/>
 <result pre="SARS-CoV-2 shares an 80% RNA sequence homology with the acute" exact="respiratory" post="syndrome-associated coronavirus (SARS-CoV).2,3 Some enzymes of both viruses show"/>
 <result pre="sequence similarity.2 Accordingly, existing drugs against SARS-CoV and Middle East" exact="Respiratory" post="Syndrome coronavirus (MERS-CoV) may be also useful to fight"/>
 <result pre="similarity.2 Accordingly, existing drugs against SARS-CoV and Middle East Respiratory" exact="Syndrome" post="coronavirus (MERS-CoV) may be also useful to fight COVID-19.1,3"/>
 <result pre="prodrug of an adenosine C-nucleoside (Figure 1A).12 By entrance into" exact="respiratory" post="epithelial cells in the human body, the prodrug may"/>
 <result pre="of an adenosine C-nucleoside (Figure 1A).12 By entrance into respiratory" exact="epithelial" post="cells in the human body, the prodrug may be"/>
 <result pre="C-nucleoside and (B) pharmacologically active nucleoside triphosphate (NTP) as a" exact="viral" post="RdRp inhibitor. The active form can prevent the replication"/>
 <result pre="can prevent the replication of several coronaviruses in the lung" exact="epithelial" post="cells. The nucleoside analog drug inhibits the RNA-dependent RNA"/>
 <result pre="generating RNA strand and causes a delayed stop in the" exact="viral" post="replication process (Figure 2).10,13 As the enzyme incorporates one,"/>
 <result pre="of steps. The nucleoside analog drug is used by the" exact="viral" post="RdRp and inhibits the enzyme by competing with the"/>
 <result pre="generating RNA strand and causes a delayed stop in the" exact="viral" post="replication process. Pharmacodynamics and Pharmacokinetics of Remdesivir The pharmacokinetics"/>
 <result pre="unapproved drug remdesivir for management of suspected or laboratory-confirmed SARS-CoV-2" exact="infection" post="in adults and pediatric patients hospitalized with severe disease.15"/>
 <result pre="an intravenous injection (IV) over 30 to 120 minutes. For" exact="adult" post="patients, a single loading dose of the drug (200"/>
 <result pre="be continued for up to 5 additional days for a" exact="total" post="treatment course of up to 10 days.15 However, in"/>
 <result pre="assays, remdesivir was an effective therapeutic against multiple variants of" exact="acute" post="Ebola virus and other filoviruses. In a rhesus monkey"/>
 <result pre="level of the nucleotide triphosphate (NTP) was observed in the" exact="peripheral" post="blood mononuclear cells (&amp;gt;10 Î¼M) for at least 24"/>
 <result pre="for at least 24 h. The half-life of remdesivir was" exact="short" post="in blood (0.39 h), but it was quickly delivered"/>
 <result pre="in blood (0.39 h), but it was quickly delivered into" exact="peripheral" post="blood mononuclear cells and converted into the active drug"/>
 <result pre="after administration. The NTP was detected in favorable organs for" exact="viral" post="replication such as testes, eyes and brain.10 Once-daily intravenous"/>
 <result pre="the virus exposure protected all infected monkeys against the lethal" exact="disease" post="and improved the clinical signs and pathophysiological indicators.10 The"/>
 <result pre="prophylaxis and early treatment in a mouse model with SARS-CoV" exact="infection" post="led to a decrease of the viral load in"/>
 <result pre="model with SARS-CoV infection led to a decrease of the" exact="viral" post="load in the lungs and improvement of the respiratory"/>
 <result pre="the viral load in the lungs and improvement of the" exact="respiratory" post="function.17 In 2020, Wang et al investigated the antiviral"/>
 <result pre="authors suggested remdesivir as a highly effective agent against SARS-CoV-2" exact="infection" post="in vitro.18 Information obtained from in vitro studies and"/>
 <result pre="was developed by Gilead Sciences. Gilead, the US Centers for" exact="Disease" post="Control and Prevention (CDC) and the US Army Medical"/>
 <result pre="Prevention (CDC) and the US Army Medical Research Institute of" exact="Infectious" post="Diseases (USAMRIID) collaborated to discover drug candidates against RNA"/>
 <result pre="(CDC) and the US Army Medical Research Institute of Infectious" exact="Diseases" post="(USAMRIID) collaborated to discover drug candidates against RNA viruses"/>
 <result pre="to induce a global pandemic (eg Ebola virus, Middle East" exact="respiratory" post="syndrome (MERS) and severe acute respiratory syndrome (SARS) coronaviruses).20â€&quot;23"/>
 <result pre="induce a global pandemic (eg Ebola virus, Middle East respiratory" exact="syndrome" post="(MERS) and severe acute respiratory syndrome (SARS) coronaviruses).20â€&quot;23 In"/>
 <result pre="(eg Ebola virus, Middle East respiratory syndrome (MERS) and severe" exact="acute" post="respiratory syndrome (SARS) coronaviruses).20â€&quot;23 In order to find suitable"/>
 <result pre="Ebola virus, Middle East respiratory syndrome (MERS) and severe acute" exact="respiratory" post="syndrome (SARS) coronaviruses).20â€&quot;23 In order to find suitable antiviral"/>
 <result pre="virus, Middle East respiratory syndrome (MERS) and severe acute respiratory" exact="syndrome" post="(SARS) coronaviruses).20â€&quot;23 In order to find suitable antiviral agents"/>
 <result pre="using remdesivir against Ebola virus in human was reported.24 Ebola" exact="meningoencephalitis" post="was diagnosed in a female nurse by detection of"/>
 <result pre="in human was reported.24 Ebola meningoencephalitis was diagnosed in a" exact="female" post="nurse by detection of Ebola virus RNA in the"/>
 <result pre="randomization to remdesivir treatment was stopped.25 Interestingly, the rate of" exact="viral" post="clearance in the subjects who received remdesivir was slower"/>
 <result pre="prophylactic and early therapeutic administration of remdesivir significantly decreased the" exact="pulmonary" post="viral loads and improved the clinical symptoms of the"/>
 <result pre="and early therapeutic administration of remdesivir significantly decreased the pulmonary" exact="viral" post="loads and improved the clinical symptoms of the disease"/>
 <result pre="pulmonary viral loads and improved the clinical symptoms of the" exact="disease" post="and lung function. It was concluded that remdesivir might"/>
 <result pre="rhesus macaques (a nonhuman primate model). Results showed that the" exact="viral" post="load in the lungs of the treated animals was"/>
 <result pre="viral load in the lungs of the treated animals was" exact="lower" post="than that of the controls. The severity of lung"/>
 <result pre="severity of lung lesions in the therapeutic treatment group was" exact="lower" post="than that in the vehicle-treated animals. The lungs of"/>
 <result pre="vitro. In mice, both prophylactic and therapeutic remdesivir improved the" exact="respiratory" post="function and decreased the pulmonary viral loads and severe"/>
 <result pre="and therapeutic remdesivir improved the respiratory function and decreased the" exact="pulmonary" post="viral loads and severe lung pathology. In contrast, prophylactic"/>
 <result pre="therapeutic remdesivir improved the respiratory function and decreased the pulmonary" exact="viral" post="loads and severe lung pathology. In contrast, prophylactic lopinavir/ritonavir-interferon"/>
 <result pre="lung pathology. In contrast, prophylactic lopinavir/ritonavir-interferon beta somewhat decreased the" exact="viral" post="loads without affecting other disease factors. Therapeutic lopinavir/ritonavir-interferon beta"/>
 <result pre="lopinavir/ritonavir-interferon beta somewhat decreased the viral loads without affecting other" exact="disease" post="factors. Therapeutic lopinavir/ritonavir-interferon beta improved pulmonary function but did"/>
 <result pre="loads without affecting other disease factors. Therapeutic lopinavir/ritonavir-interferon beta improved" exact="pulmonary" post="function but did not reduce virus replication or severe"/>
 <result pre="pathology. Overall, the authors suggested that remdesivir might improve the" exact="disease" post="outcomes in coronavirus-infected patients, be useful to protect health"/>
 <result pre="with COVID-19 was compassionately treated with intravenous remdesivir after developing" exact="pneumonia" post="in the USA.27 The patient was hospitalized for more"/>
 <result pre="and clinical information of the subjects, data on course of" exact="infection" post="and clinical care were interpreted. Seven of 12 patients"/>
 <result pre="interpreted. Seven of 12 patients (58%) with radiographic signs of" exact="pneumonia" post="and clinical or laboratory clues of worsening in the"/>
 <result pre="laboratory clues of worsening in the second week of the" exact="infection" post="were hospitalized. Three hospitalized patients received investigational antiviral remdesivir"/>
 <result pre="levels were elevated and temporary abdominal symptoms including nausea, vomiting," exact="gastroparesis" post="or rectal hemorrhage were observed. No post-remdesivir symptom was"/>
 <result pre="observed. No post-remdesivir symptom was detected. After recovery of the" exact="respiratory" post="symptoms, the drug was stopped.28 In 2020, in a"/>
 <result pre="basis to patients with severe COVID-19. Patients with confirmed SARS-CoV-2" exact="infection" post="and breathing oxygen support or receiving ambient air were"/>
 <result pre="al (2020) conducted a randomized, double-blind, placebo-controlled, multicenter trial in" exact="adult" post="patients with COVID-19 at ten hospitals in China (ClinicalTrials.gov"/>
 <result pre="mg once-daily) while hospitalized for up to 10 days.35 The" exact="primary" post="outcome of the trial is time to recovery. Day"/>
 <result pre="Sciences, is enrolling patients with severe COVID-19 (ClinicalTrials.gov identifier: NCT04292899)." exact="Primary" post="outcomes are the odds of ratio for improvement on"/>
 <result pre="except patients enrolling in that study undergo moderate COVID-19. The" exact="primary" post="outcome is the proportion of subjects discharged by day"/>
 <result pre="100 mg once-daily for remaining days.39,40 In both trials, the" exact="primary" post="outcome measure is the time to clinical recovery. The"/>
 <result pre="of study medicine (active or placebo) until normalization of fever," exact="respiratory" post="rate, oxygen saturation and alleviation of cough, sustained for"/>
 <result pre="to evaluate the efficacy and safety of remdesivir in hospitalized" exact="adult" post="patients with severe COVID-19 Terminated China April 10, 2020"/>
 <result pre="the effects of remdesivir in the treatment of severe COVID-19" exact="infections" post="Recruiting France June 2020 NCT04302766 An intermediate-size patient population"/>
 <result pre="An intermediate-size patient population expanded access treatment protocol for coronavirus" exact="disease" post="2019 (COVID-19) using remdesivir (RDV; GS-5734â&quot;¢) Available â€&quot; â€&quot;"/>
 <result pre="to evaluate the efficacy and safety of remdesivir in hospitalized" exact="adult" post="patients with mild and moderate COVID-19 Suspended China April"/>
 <result pre="protocol: remdesivir (RDV; GS-5734) for the treatment of SARS-CoV-2 (CoV)" exact="infection" post="Available â€&quot; â€&quot; NCT04410354 A phase 2, randomized, double-blind,"/>
 <result pre="safety of oral merimepodib in combination with intravenous remdesivir in" exact="adult" post="patients with advanced coronavirus disease 2019 (COVID-19) Recruiting USA"/>
 <result pre="combination with intravenous remdesivir in adult patients with advanced coronavirus" exact="disease" post="2019 (COVID-19) Recruiting USA August 2020 NCT04292730 A phase"/>
 <result pre="with remdesivir plus placebo in hospitalized patients with severe COVID-19" exact="pneumonia" post="Recruiting â€&quot; July 31, 2020 NCT04431453 A phase 2/3,"/>
 <result pre="this work. References References 1.CaoYC, DengQX, DaiSX. Remdesivir for severe" exact="acute" post="respiratory syndrome coronavirus 2 causing COVID-19: an evaluation of"/>
 <result pre="work. References References 1.CaoYC, DengQX, DaiSX. Remdesivir for severe acute" exact="respiratory" post="syndrome coronavirus 2 causing COVID-19: an evaluation of the"/>
 <result pre="References References 1.CaoYC, DengQX, DaiSX. Remdesivir for severe acute respiratory" exact="syndrome" post="coronavirus 2 causing COVID-19: an evaluation of the evidence."/>
 <result pre="the past: possible urgent prevention and treatment options for severe" exact="acute" post="respiratory infections caused by 2019-nCoV. Chembiochem. 2020;21(5):730â€&quot;738. doi:10.1002/cbic.20200004732022370 3.KoWC,"/>
 <result pre="past: possible urgent prevention and treatment options for severe acute" exact="respiratory" post="infections caused by 2019-nCoV. Chembiochem. 2020;21(5):730â€&quot;738. doi:10.1002/cbic.20200004732022370 3.KoWC, RolainJM,"/>
 <result pre="possible urgent prevention and treatment options for severe acute respiratory" exact="infections" post="caused by 2019-nCoV. Chembiochem. 2020;21(5):730â€&quot;738. doi:10.1002/cbic.20200004732022370 3.KoWC, RolainJM, LeeNY,"/>
 <result pre="2020;19(3):149â€&quot;150. doi:10.1038/d41573-020-00016-032127666 5.LoMK, FeldmannF, GaryJM, et al. Remdesivir (GS-5734) protects" exact="African" post="green monkeys from Nipah virus challenge. Sci Transl Med."/>
 <result pre="compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East" exact="respiratory" post="syndrome coronavirus. J Biol Chem. 2020;295(15):4773â€&quot;4779. doi:10.1074/jbc.AC120.01305632094225 7.SheahanTP, SimsAC,"/>
 <result pre="remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory" exact="syndrome" post="coronavirus. J Biol Chem. 2020;295(15):4773â€&quot;4779. doi:10.1074/jbc.AC120.01305632094225 7.SheahanTP, SimsAC, LeistSR,"/>
 <result pre="Nucleotide prodrug GS-5734 is a broad-spectrum filovirus inhibitor that provides" exact="complete" post="therapeutic protection against the development of Ebola virus disease"/>
 <result pre="provides complete therapeutic protection against the development of Ebola virus" exact="disease" post="(EVD) in infected non-human primatesOpen Forum Infectious Diseases. Vol."/>
 <result pre="of Ebola virus disease (EVD) in infected non-human primatesOpen Forum" exact="Infectious" post="Diseases. Vol. 2Infectious Diseases Society of America; 2015: LBâ€&quot;2."/>
 <result pre="(EVD) in infected non-human primatesOpen Forum Infectious Diseases. Vol. 2Infectious" exact="Diseases" post="Society of America; 2015: LBâ€&quot;2. 9.MulanguS, DoddLE, DaveyRTJr, et"/>
 <result pre="DaveyRTJr, et al. A randomized, controlled trial of Ebola virus" exact="disease" post="therapeutics. N Engl J Med. 2019;381(24):2293â€&quot;2303. doi:10.1056/NEJMoa191099331774950 10.WarrenTK, JordanR,"/>
 <result pre="analog GS-441524 for treatment of cats with naturally occurring feline" exact="infectious" post="peritonitis. J Feline Med Surg. 2019;21(4):271â€&quot;281. doi:10.1177/1098612X1982570130755068 12.SiegelD, HuiHC,"/>
 <result pre="remdesivir. Viruses. 2019;11(4):326. doi:10.3390/v11040326 14.AgostiniML, AndresEL, SimsAC, et al. Coronavirus" exact="susceptibility to" post="the antiviral remdesivir (GS-5734) is mediated by the viral"/>
 <result pre="susceptibility to the antiviral remdesivir (GS-5734) is mediated by the" exact="viral" post="polymerase and the proofreading exoribonuclease. MBio. 2018;9(2):e00221â€&quot;18. doi:10.1128/mBio.00221-1829511076 15.Available"/>
 <result pre="28.collab: The COVID-19 Investigation Team. First 12 Patients with Coronavirus" exact="Disease" post="2019 (COVID-19) in the United States. Preprint; 2020. 29.GreinJ,"/>
 <result pre="30.KujawskiSA, WongKK, CollinsJP, et al. First 12 Patients with Coronavirus" exact="Disease" post="2019 (COVID-19) in the United States. medRxiv; 2020. 31.LescureFX,"/>
 <result pre="antiviral activity of remdesivir (GS-5734â&quot;¢) in participants with severe coronavirus" exact="disease" post="(COVID-19). Available from: https://clinicaltrials.gov/ct2/show/NCT04292899. Accessed 721, 2020. 38.collab: U.S."/>
 <result pre="antiviral activity of remdesivir (GS-5734â&quot;¢) in participants with moderate coronavirus" exact="disease" post="(COVID-19) compared to standard of care treatment. Available from:"/>
 <result pre="2020. 40.collab: U.S. National Library of Medicine Clinical Trials Registry." exact="Severe" post="2019-nCoV remdesivir RCT; 2020Available from: https://clinicaltrials.gov/ct2/show/NCT04257656. Accessed 721, 2020."/>
</results>
